Sini Decoction Ameliorates Colorectal Cancer and Modulates the Composition of Gut Microbiota in Mice

Wang, Yishan; Zhang, Xiaodi; Li, Jiawei; Zhang, Ying; Guo, Yingjie; Chang, Qing; Chen, Li; Wang, Yiwei; Wang, Siyao; Song, You-Jin; Zhao, Yongkun; Wang, Zhihong

doi:10.3389/fphar.2021.609992

Cited by 15 publications

(10 citation statements)

References 62 publications

(64 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AM in combination with current anti-tumor therapies, including cisplatin treatment and IL-2-based immunotherapy, is also a promising treatment strategy [ 51 , 52 ]. In addition, the drug treatments of castration-resistant prostate cancer [ 53 ], pancreatic ductal adenocarcinoma [ 54 ], lung cancer [ 55 ], and colorectal cancer [ 56 , 57 ] may also be driven by AM.…”

Section: Native Probiotics and Diseasesmentioning

confidence: 99%

Native and Engineered Probiotics: Promising Agents against Related Systemic and Intestinal Diseases

Shen

Zhao

et al. 2022

IJMS

View full text Add to dashboard Cite

Intestinal homeostasis is a dynamic balance involving the interaction between the host intestinal mucosa, immune barrier, intestinal microecology, nutrients, and metabolites. Once homeostasis is out of balance, it will increase the risk of intestinal diseases and is also closely associated with some systemic diseases. Probiotics (Escherichia coli Nissle 1917, Akkermansia muciniphila, Clostridium butyricum, lactic acid bacteria and Bifidobacterium spp.), maintaining the gut homeostasis through direct interaction with the intestine, can also exist as a specific agent to prevent, alleviate, or cure intestinal-related diseases. With genetic engineering technology advancing, probiotics can also show targeted therapeutic properties. The aims of this review are to summarize the roles of potential native and engineered probiotics in oncology, inflammatory bowel disease, and obesity, discussing the therapeutic applications of these probiotics.

show abstract

Section: Native Probiotics and Diseasesmentioning

confidence: 99%

Native and Engineered Probiotics: Promising Agents against Related Systemic and Intestinal Diseases

Shen

Zhao

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…And this may be related to its ability to change the abundance of the mouse intestinal microbes. It can reduce the abundance of Bacteroides fragilis and Sulphate-reducing bacteria and increase the abundance of Lactobacillus , Bacillus coagulans , Akkermansia muciniphila , and Bifidobacterium [ 84 ].…”

Section: Application Of Gut Microbiota In Tumor Immunotherapymentioning

confidence: 99%

The Role of Gut Microbiota in Tumor Immunotherapy

Bai

et al. 2021

Journal of Immunology Research

View full text Add to dashboard Cite

Tumor immunotherapy is the fourth therapy after surgery, chemotherapy, and radiotherapy. It has made great breakthroughs in the treatment of some epithelial tumors and hematological tumors. However, its adverse reactions are common or even more serious, and the response rate in some solid tumors is not satisfactory. With the maturity of genomics and metabolomics technologies, the effect of intestinal microbiota in tumor development and treatment has gradually been recognized. The microbiota may affect tumor immunity by regulating the host immune system and tumor microenvironment. Some bacteria help fight tumors by activating immunity, while some bacteria mediate immunosuppression to help cancer cells escape from the immune system. More and more studies have revealed that the effects and complications of tumor immunotherapy are related to the composition of the gut microbiota. The composition of the intestinal microbiota that is sensitive to treatment or prone to adverse reactions has certain characteristics. These characteristics may be used as biomarkers to predict the prognosis of immunotherapy and may also be developed as “immune potentiators” to assist immunotherapy. Some clinical and preclinical studies have proved that microbial intervention, including microbial transplantation, can improve the sensitivity of immunotherapy or reduce adverse reactions to a certain extent. With the development of gene editing technology and nanotechnology, the design and development of engineered bacteria that contribute to immunotherapy has become a new research hotspot. Based on the relationship between the intestinal microbiota and immunotherapy, the correct mining of microbial information and the development of reasonable and feasible microbial intervention methods are expected to optimize tumor immunotherapy to a large extent and bring new breakthroughs in tumor treatment.

show abstract

“…In SND-treated mice, the abundance of pathogenic bacteria decreased, while the abundance of some bacteria increased, such as Lactobacillus , Bacillus coagulans and A. muciniphila. [ 91 ]…”

Section: Strategies Of Microbe-based Managementmentioning

confidence: 99%

“…In SND-treated mice, the abundance of pathogenic bacteria decreased, while the abundance of some bacteria increased, such as Lactobacillus, Bacillus coagulans and A. muciniphila. [91] Overall, TCM can effectively prevent CRC development by regulating the intestinal microbiota and further regulating the immune system, including the inflammatory cytokines or tumor-related pathways.…”

Section: Dietary Interventionsmentioning

confidence: 99%

Microbe-based management for colorectal cancer

Gao

Cui

Yan

et al. 2021

Chinese Medical Journal

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most prevalent, most lethal cancers in the world. Increasing evidence suggests that the intestinal microbiota is closely related to the pathogenesis and prognosis of CRC. The normal microbiota plays an essential role in maintaining gut barrier function and the immune microenvironment. Recent studies have identified carcinogenic bacteria such as enterotoxigenic Bacteroides fragilis ( ETBF ) and Streptococcus gallolyticus ( S. gallolyticus ), as well as protective bacterial such as Akkermansia muciniphila ( A. muciniphila ), as potential targets of CRC treatment. Gut microbiota modulation aims to restore gut dysbiosis, regulate the intestinal immune system and prevent from pathogen invasion, all of which are beneficial for CRC prevention and prognosis. The utility of probiotics, prebiotics, postbiotics, fecal microbiota transplantation and dietary inventions to treat CRC makes them novel microbe-based management tools. In this review, we describe the mechanisms involved in bacteria-derived colorectal carcinogenesis and summarized novel bacteria-related therapies for CRC. In summary, we hope to facilitate clinical applications of intestinal bacteria for preventing and treating CRC.

show abstract

Sini Decoction Ameliorates Colorectal Cancer and Modulates the Composition of Gut Microbiota in Mice

Cited by 15 publications

References 62 publications

Native and Engineered Probiotics: Promising Agents against Related Systemic and Intestinal Diseases

Native and Engineered Probiotics: Promising Agents against Related Systemic and Intestinal Diseases

The Role of Gut Microbiota in Tumor Immunotherapy

Microbe-based management for colorectal cancer

Contact Info

Product

Resources

About